Platelet function tests and flow cytometry to monitor antiplatelet therapy

被引:43
作者
Matzdorff, A [1 ]
机构
[1] Caritasklin St Theresia, Dept Hematol & Oncol, D-66113 Saarbrucken, Germany
关键词
platelet function; aggregometry; Rapid-Platelet-Function-Analyzer; PFA-100; flow cytometry;
D O I
10.1055/s-2005-916672
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There are numerous methods to measure platelet function in specialized laboratories. They provide valuable results for research or small patient studies, but none of these tests is currently used to guide antiplatelet therapy in routine clinical practice. Aggregometry is the most commonly used test, but this technique is time-consuming and preanalytical preparation, choice of anticoagulant, and agonist have not been standardized. The Rapid-Platelet-Function-Analyzer uses whole blood to measure glycoprotein (GP) IIb/III inhibitor activity. This test is quick and simple and results for abciximab correlate closely with aggregometry. The platelet function analyzer PFA-100 is a good screening method to detect platelet function defects. The closure time of the PFA is also sensitive for aspirin-resistance that affects many patients. Flow cytometry can monitor a whole panel of platelet activation markers and platelet interactions with other cells. It can quantitate receptor expression and inhibition. Although cytometry is time-consuming and expensive, it is a valuable tool for research. Platelets have many different functions. This requires specific tests optimized for each of the different functions. Each test has advantages and disadvantages and should be interpreted only in concert with a thorough history and physical examination. The ideal test should be simple, quick, inexpensive, and available on a 24-hour basis.
引用
收藏
页码:393 / 399
页数:7
相关论文
共 62 条
[51]   Rapid platelet-function assay - An automated and quantitative cartridge-based method [J].
Smith, JW ;
Steinhubl, SR ;
Lincoff, AM ;
Coleman, JC ;
Lee, TT ;
Hillman, RS ;
Coller, BS .
CIRCULATION, 1999, 99 (05) :620-625
[52]   Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention [J].
Steinhubl, SR ;
Kottke-Marchant, K ;
Moliterno, DJ ;
Rosenthal, ML ;
Godfrey, NK ;
Coller, BS ;
Topol, EJ ;
Lincoff, AM .
CIRCULATION, 1999, 100 (19) :1977-1982
[53]  
Steinhubl SR, 2001, CIRCULATION, V103, P2572
[54]  
Storey RF, 1999, THROMB HAEMOSTASIS, V82, P1307
[55]   Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency - Implications for assay methodology and comparison of different antagonists [J].
Storey, RF ;
Wilcox, RG ;
Heptinstall, S .
CIRCULATION, 1998, 98 (16) :1616-1621
[56]   PARTICLE-VOLUME CHANGES ASSOCIATED WITH LIGHT TRANSMITTANCE CHANGES IN THE PLATELET AGGREGOMETER - DEPENDENCE UPON AGGREGATING AGENT AND EFFECTIVENESS OF STIMULUS [J].
THOMPSON, NT ;
SCRUTTON, MC ;
WALLIS, RB .
THROMBOSIS RESEARCH, 1986, 41 (05) :615-626
[57]  
Topol CE, 2000, LANCET, V355, P337
[58]   PLATELET HYPERREACTIVITY AND PROGNOSIS IN SURVIVORS OF MYOCARDIAL-INFARCTION [J].
TRIP, MD ;
CATS, VM ;
VANCAPELLE, FJL ;
VREEKEN, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (22) :1549-1554
[59]   A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions [J].
Varon, D ;
Dardik, R ;
Shenkman, B ;
KotevEmeth, S ;
Farzame, N ;
Tamarin, I ;
Savion, N .
THROMBOSIS RESEARCH, 1997, 85 (04) :283-294
[60]   Cardiopulmonary bypass leads to a preferential loss of activated platelets - A flow cytometric assay of platelet surface antigens [J].
Wahba, A ;
Black, G ;
Koksch, M ;
Rothe, G ;
Preuner, J ;
Schmitz, G ;
Birnbaum, DE .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1996, 10 (09) :768-773